Indication
Prophylaxis of migraine in adults who have at least 4 migraine days per month
Medicine details
- Medicine name:
- galcanezumab (Emgality)
- SMC ID:
- SMC2313
- Pharmaceutical company
- Eli Lilly and Company Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Publication due date:
- 12 April 2021
- SMC meeting date:
- 02 March 2021
- Patient group submission deadline:
- 01 February 2021